Physician profile
Anitha Vyza
NPI 1144220716
$3,452.30
in general payments reported to CMS, 2019-2025
29 companies · $651 in 2025
The $651 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $165 · 2021: $115 · 2022: $576 · 2023: $447 · 2024: $589 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,687.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $496.44 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.81 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $398.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $351.72 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Astrazeneca Pharmaceuticals Lp | $286.42 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $280.85 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $215.10 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $160.65 | 2019-2020 | |
| Boston Scientific Corporation | $112.02 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Optinose US, INC. | $90.43 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $72.39 | 2019-2022 | |
| Allergan, INC. | $63.66 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.87 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $39.25 | 2022 | |
| Janssen Pharmaceuticals, INC | $38.17 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $37.73 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $35.89 | 2025 | Veozah |
| Amgen INC. | $35.79 | 2019-2024 | Evenity, Prolia |
| Neurocrine Biosciences, INC. | $34.54 | 2025 | |
| Amarin Pharma, INC. | $31.48 | 2019 | |
| Inogen, INC. | $22.94 | 2025 | |
| Medtronic, INC. | $22.06 | 2022 | |
| Abbvie INC. | $21.71 | 2025 | |
| Gilead Sciences, INC. | $21.09 | 2024 | |
| Biotronik Nro, INC. | $20.78 | 2025 | Prospera |
| Exact Sciences Corporation | $18.37 | 2025 | The Cologuard Plus Collection Kit |
| Seqirus USA INC | $17.67 | 2024 | Flucelvax, Fluad |
| Vbi Vaccine (Delaware) INC. | $14.06 | 2022 | |
| Insulet Corporation | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anitha Vyza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.